Intrahepatic Cholangiocarcinoma - 20/08/11

Doi : 10.1016/j.suc.2010.04.011

George A. Poultsides, MD ^a, Andrew X. Zhu, MD ^b,^c, Michael A. Choti, MD, MBA ^d, Timothy M. Pawlik, MD, MPH ^e,^⁎
^a Department of Surgery, Division of Surgical Oncology, Stanford University School of Medicine, 300 Pasteur drive, H3680, Stanford, CA 94305-5641, USA
^b Department of Medicine, Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, LH/POB 232, Boston, MA 02114, USA
^c Department of Surgery, Liver Cancer Research Program, Massachusetts General Hospital, 55 Fruit Street, LH/POB 232, Boston, MA 02114, USA
^d Department of Surgery, Division of Surgical Oncology, Johns Hopkins Medical Institutions, 600 N Wolfe Street, Blalock 665, Baltimore, MD 21287, USA
^e Department of Surgery, Johns Hopkins Medical Institutions, 600 N Wolfe Street, Harvey 611, Baltimore, MD 21287, USA

Corresponding author.

Résumé

Intrahepatic cholangiocarcinoma (ICC) is a primary cancer of the bile ducts, arising from malignant transformation of the epithelial cells that line the biliary apparatus. ICC is relatively uncommon, but its incidence is on the increase. ICC is frequently discovered as an incidental, indeterminate liver mass. Surgical resection of ICC represents the only potentially curative therapeutic option. The role of routine hilar lymphadenectomy is controversial, but should be considered to optimize staging. Although adjuvant chemotherapy and radiotherapy is probably not supported by current data, each should strongly be considered in patients with lymph node metastasis or an R1 resection. For those patients with inoperable disease, locoregional therapy with transarterial chemoembolization can be considered.

Le texte complet de cet article est disponible en PDF.

Keywords : Peripheral cholangiocarcinoma, Biliary cancer, Liver cancer, Liver resection, Hepatectomy